This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
17 Jan 2012

Shire Acquires US Rights to Resolor

Shire plc has acquired the rights to develop and market Resolor(R) (prucalopride) in the US.

Specialty biopharmaceutical company Shire plc has acquired the rights to develop and market Resolor(R) (prucalopride) in the US in an agreement with Janssen Pharmaceutica N.V.

 

Under the terms of the agreement, the US rights to the Resolor trademark will be transferred to Shire.

 

Resolor, a prokinetic, is part of Shire's gastrointestinal (GI) portfolio in Europe and is approved for use in 33 countries for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Resolor is currently available in Germany, Ireland, Belgium, France, Greece and the United Kingdom, and will be commercially available in Italy in mid-January 2012. Additional launches throughout Europe are planned for 2012.

Related News